-- 獨立研究機構CFRA向提供了以下研究報告。 CFRA分析師總結如下：Neurocrine公司2026年第一季業績強勁，總銷售額達8.11億美元（年成長44%），顯著超越預期，反映出旗下兩大產品線均呈現強勁成長動能。 INGREZZA維持在市場領先地位，銷售額達6.569億美元（年增20%），而CRENESSITY的銷售額則從上年的1,450萬美元增至1.533億美元，實現了顯著的收入多元化。我們認為，成功的多元化策略驗證了罕見內分泌疾病領域的商業潛力，並鞏固了NBIX的策略地位。管理層重申了2026年全年INGREZZA銷售額27億至28億美元的預期，體現了對公司持續成長的信心。已宣布以29億美元收購Soleno（預計將於2026年第二季完成），這將使NBIX的罕見疾病產品組合新增用於治療普拉德-威利症候群的VYKAT XR。憑藉26.5億美元的充裕現金儲備以及多項正在推進臨床開發的在研產品，我們相信NBIX已做好充分準備，在神經精神病學和內分泌學領域保持增長勢頭，並拓展其治療業務。
Related Articles
Research
Research Alert: Expd: Q1 Results Top Expectations
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:EXPD delivered strong Q1 results, with EPS of $1.71 versus $1.47 prior year, significantly beating our $1.37 estimate and $1.33 consensus forecast. Revenue rose 4% to $2.7B from $2.67B, exceeding our $2.59B forecast as Airfreight and Customs strength offset Ocean weakness. Mixed segment performance reflected market bifurcation, with Airfreight revenue surging 14% to $1.03B on favorable pricing while Ocean revenue plummeted 23% to $599M due to capacity oversupply pressuring both pricing and volumes. Management expects global capacity oversupply to persist near-term despite maintaining Ocean profitability. Customs/Other revenue jumped 17% to $1.15B, with double-digit growth across all products, due to hyperscaler and high-value technology customer demand plus tariff complexity. Operating margins reached the company's 30% target despite Middle East disruptions, with productivity gains from 2025 AI and technology investments beginning to materialize.
$EXPD
International
New Zealand's Jobless Rate Falls in March Quarter
New Zealand's seasonally-adjusted unemployment rate fell to 5.3% in the March quarter from 5.4% in the December 2025 quarter, data from Stats NZ showed on Wednesday.The seasonally-adjusted number of unemployed people for the quarter was 163,000, down from 165,000 for the December 2025 quarter.The underutilization rate was unchanged at nearly 13% in the quarter, while the participation rate slid 70.4% from 70.5% in the December 2025 quarter.The seasonally-adjusted employment rate was flat at about 67%.The seasonally adjusted youth not in employment, education, or training (NEET) rate rose to over 14% in the March quarter, up from over 13% in the December 2025 quarter."Women aged 20 to 24 continue to have the highest NEET rate, rising 1.9 percentage points to 20.3% in the March quarter," labor market spokesperson Abby Johnston said.
$^NZ50
Research
Research Alert: Emerson Electric: Fq2 Eps Beats Despite Sales Growth Slowdown
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:EMR delivered operating EPS growth of 4% Y/Y to $1.54, though underlying sales growth moderated to 0.5%, impacted by the U.S.-Iran conflict according to management. The beat was supported by share buyback activity. We see 5% underlying orders growth signaling a future recovery, with bookings centered in the high-margin Software & Systems business. Management expects Software segment profitability to enter modest recovery in 2H FY 26. The Software & Systems platform delivered 4% reported growth, with Test & Measurement achieving 16% reported growth, reflecting sustained demand in EMR's growth verticals including semiconductor and aerospace markets. Geographic performance revealed mixed fortunes, with Americas leading growth at 5% Y/Y, while Europe declined 4% and Asia/MEA fell 5%, reflecting broader geopolitical tensions. Adjusted segment EBITA margin compressed 40 bps Y/Y to 27.6% despite favorable mix shift toward higher-margin Software & Systems, with Software margins declining 250 bps to 29.2%.
$EMR